Answers are grounded in this paper and cite their sources.
A nation‐wide screening for HbA1cwas carried out in Denmark. Twenty‐one paediatric departments treating children with Type 1 diabetes participated. During a period of 4 months 884 children were included, 93% of all those followed at these centres, representing approximately 70–80% of all children and adolescents with Type 1 diabetes in Denmark. Among the children 351 were ≤ 12 years and 533 were adolescents between 12 and 18 years. Children ≤ 12 years had a HbA1cconcentration of 8.9 ± 1.5 (± SD)% and an insulin dose of 0.71 ± 0.3 U kg−124‐h−1. For adolescents HbA1cwas significantly higher 9.7 ± 2.0% (p< 0.001) and insulin dose significantly increased 0.85 ± 0.3 U kg−124‐h−1(p< 0.001). Normal range for HbA1c' is 4.0–6.5 (mean 5.3)% of total haemoglobin. Boys and girls ≤ 12 years had similar HbA1c' but girls received 13% more insulin (p< 0.001). In the group of adolescents, girls had a HbA1c4% higher than boys (9.9 ± 2.0 vs 9.5 ± 2.0%p< 0.025), received 11% more insulin (p< 0.001), and had 6% higher body mass index (p< 0.001). A weak correlation was found between insulin dose and the HbA1clevel (r= 0.29,p< 0.001). Children and adolescents on four or more injections daily received significantly more insulin (p< 0.001) than those on conventional treatment and had a significantly higher body mass index (p< 0.001). These changes were most pronounced for girls who, despite receiving 15% more insulin, had a significantly higher HbA1clevel (9.9 ± 1.8 vs 9.3 ± 1.9%,p< 0.005) and 12% higher body mass index (p< 0.001). Furthermore standard deviation score for height decreased with longer duration of the disease and more so in children with the highest HbA1cvalues. Our data confirm that current treatment of childhood diabetes in Denmark produces unsatisfactory results.
No takes yet. Share an insight, caveat, or question.
Mortensen et al. (1988) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: